- Cdc25 phosphatases are essential regulators of the eukaryotic cell cycle, functioning as activators of cyclin‑dependent kinases (CDKs) that drive progression through key transitions. In mammals, three isoforms—Cdc25A, Cdc25B and Cdc25C—work together to control the G1–S and G2–M transitions. Their ability to remove inhibitory phosphates from CDKs makes them indispensable for initiating DNA replication, promoting mitotic entry and coordinating checkpoint responses. Because of their central role in proliferation, Cdc25 phosphatases are tightly regulated and frequently dysregulated in cancer.
- During the G2 phase, Cdc25 activates the Cyclin B–CDK1 complex, the master driver of mitotic entry. CDK1 is kept inactive by inhibitory phosphorylation on threonine‑14 and tyrosine‑15, mediated by Wee1 and Myt1 kinases. Cdc25 removes these inhibitory phosphates, converting CDK1 into its active form and triggering the onset of mitosis. This activation initiates a positive feedback loop: active CDK1 phosphorylates Cdc25, further enhancing its activity, while simultaneously inhibiting Wee1. This feedback ensures a rapid, switch‑like transition into mitosis.
- Cdc25 also plays a major role in the G1–S transition. Cdc25A, in particular, activates Cyclin E–CDK2 and Cyclin A–CDK2, promoting DNA replication. Because of this, Cdc25A is highly sensitive to DNA damage. When replication stress or DNA lesions occur, the ATR–Chk1 pathway rapidly targets Cdc25A for degradation, preventing CDK2 activation and halting S‑phase progression. This checkpoint‑dependent inhibition protects cells from replicating damaged DNA and maintains genomic stability.
- Cdc25 phosphatases are tightly regulated by phosphorylation, ubiquitination and subcellular localisation. Under normal conditions, Cdc25C is kept inactive in the cytoplasm through phosphorylation by Chk1, which promotes binding to 14‑3‑3 proteins. When DNA damage is detected, Chk1 and Chk2 phosphorylate Cdc25A and Cdc25C, leading to their degradation or sequestration. This prevents premature CDK activation and enforces cell‑cycle arrest. Conversely, mitotic kinases such as Plk1 phosphorylate Cdc25 to enhance its activity and promote mitotic entry.
- The role of Cdc25 in cancer is significant. Many tumours show overexpression of Cdc25A or Cdc25B, which correlates with high proliferation rates, genomic instability and poor prognosis. Excessive Cdc25 activity can override checkpoint controls, allowing cells with DNA damage to enter S phase or mitosis. This contributes to mutation accumulation and tumour progression. Because of this, Cdc25 phosphatases are being explored as potential therapeutic targets. Inhibiting Cdc25 may selectively impair tumour cells that rely on rapid, checkpoint‑deficient division.
- At the structural level, Cdc25 phosphatases belong to the dual‑specificity phosphatase family, capable of removing phosphates from both serine/threonine and tyrosine residues. Their catalytic domain contains a conserved cysteine essential for phosphatase activity. The N‑terminal regulatory region integrates signals from checkpoint kinases, mitotic kinases and ubiquitin ligases, allowing Cdc25 to respond dynamically to cellular conditions.
- In summary, Cdc25 phosphatases are master regulators of CDK activation, controlling both the G1–S and G2–M transitions. Their precise regulation ensures that cells replicate DNA only when conditions are favourable and enter mitosis only when the genome is intact. Dysregulation of Cdc25 disrupts these safeguards, contributing to uncontrolled proliferation and cancer development. Understanding Cdc25 provides deep insight into cell‑cycle control, checkpoint signalling and tumour biology.
